Unihealth pushes 1,000-bed target to 2028, Uganda still 82% of revenue
Earlier commitments on geographic mix and a Tanzania syringe plant have been abandoned. EBITDA margins are set to compress from low-40s to mid-30s as new beds add costs.
— 1 earlier story on Unihealth Hospitals Ltd. →What's new
- 1,000-bed target delayed over two years; current base at 400 beds.
- Uganda still 82% of revenue vs earlier goal of 25-30%.
- Tanzania syringe plant abandoned; site repurposed for hospital beds.
Why this matters
Unihealth is walking away from two key earlier promises: geographic diversification and a non-hospital venture. Margins are set to compress from the low-40s to mid-30s, and PAT margin guidance for FY27 is just 8-10%. For a stock trading at 35x trailing earnings, execution credibility is now the open question.
What we're watching
- Whether the Dar es Salaam acquisition and Mwanza facility actually add 120 beds by 2028.
- How quickly receivables improve in India vs Uganda's 320-day cycle.
- Any further delays or abandonment of expansion plans.
The full read
Unihealth Hospitals has pushed its 1,000‑bed target from FY26 to the end of CY2028. Only 400 beds are commissioned today. Uganda still generated 82% of FY26 revenue, missing an earlier goal to cap any single geography at 25‑30%. A planned syringe plant in Tanzania has been scrapped — the Mwanza site will now be used for hospital beds instead. Promises are being abandoned one by one. Consolidated EBITDA margins are expected to fall from the low‑40s to the mid‑30s as new facilities burn cash, and PAT margin guidance for FY27 is just 8‑10%. The call outlined plans to add 120 beds in Tanzania via a Dar es Salaam acquisition and a secondary‑care facility in Mwanza, while improved payer mixes in India offer shorter receivables. But Uganda’s 320‑day receivable cycle remains a drag. With the stock already trading at 35x trailing earnings, each delay erodes the premium that relied on muscular growth assumptions — assumptions that the conference call systematically walked back.
Questions answered
- Why did Unihealth delay its 1,000-bed target?
- Management cited slower-than-expected commissioning. The target has been pushed from FY26 to end of CY2028. Current commissioned beds are 400.
- What happened to the syringe manufacturing plant in Tanzania?
- The plant has been abandoned. The site at Mwanza is now described as part of the hospital bed expansion, not a separate manufacturing venture.
- How concentrated is Unihealth's revenue by geography?
- Uganda contributed 82% of revenue in FY26, far from the earlier commitment to reduce any single geography's share to 25-30% by the same period.
- What is the expected margin compression?
- Consolidated EBITDA margins are expected to compress from the low-40s to the mid-30s due to start-up costs and depreciation from new facilities. PAT margin guidance for FY27 is 8-10%.
Unihealth Hospitals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on UNIHEALTH →- 30 Jun 2026 · 6:54 PM IST Unihealth pushes 1,000-bed target to 2028, Uganda still 82% of revenue
- 33d ago Unihealth's Ugandan receivables hit 320 days; Tanzania plant scrapped